Streamlining Population PK Modeling with Phoenix NLME & Pirana: Bridging Efficiency and Precision in Pharmacometrics [APAC Webinar] On-Demand Webinar Phoenix NLME & Pirana 双擎驱动:群体 PK 建模高效精准实战解析 [亚太地区网络研讨会] Senior Director, Pharmacometric Software, Certara Keith has more than 20 years of global drug development…Certara2025 年 4 月 24 日
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study Publication HIV 病毒学抑制青少年中长效注射用 cabotegravir 与长效注射用 rilpivirine 联合用药的安全性研究(IMPAACT 2017/MOCHA):一项 1/2 期、多中心、开放标签、非比较性的剂量探索研究 The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…Certara2025 年 3 月 20 日
The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer Reimbursement Publication The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer Reimbursement This article explores the overlooked yet critical role of early strategic planning for payer reimbursement…Certara2025 年 2 月 25 日
Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling Video Certara Phoenix 平台 — 全球最值得信赖的药代动力学/药效学(PK/PD)分析与建模平台 Today’s drug candidates are more complex than ever. But with development decisions on the line,…Certara2025 年 2 月 12 日
Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies Publication 针对复发难治性(R/R)骨髓纤维化(MF)及其他髓系或实体瘤恶性肿瘤患者的 Navtemadlin 群体药代动力学与药效学分析 This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…Certara2025 年 2 月 6 日
Understanding Variability in CAR-T Cell Therapy Kinetics Publication 了解 CAR-T 细胞疗法动力学的变异性 Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates…Certara2025 年 1 月 23 日
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease Publication INTERCEPT-AD:一项针对阿尔茨海默病所致轻度认知障碍或轻度痴呆患者的静脉注射 Sabirnetug 的 I 期研究 The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…Certara2025 年 1 月 8 日
Advancing pharmacometrics in Africa – Transition from capacity development toward job creation Publication 推动非洲定量药理学的发展 — 从能力建设向创造就业过渡 This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…Certara2024 年 12 月 9 日
Recent applications of pharmacometrics and systems pharmacology approaches to improve and optimize drug therapy for pregnant and lactating women Publication 定量药理学和系统药理学方法在改善和优化孕妇和哺乳期妇女药物治疗方面的最新应用 The article "Recent Applications of Pharmacometrics and Systems Pharmacology Approaches to Improve and Optimize Drug…Certara2024 年 11 月 18 日